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A B S T R A C T
The aim of this study was to evaluate the usefulness of a short form of the WHOQOL questionnaire, the WHOQOL-
-BREF, which consists of 24 questions, in evaluating quality of life (QOL) in sarcoidosis patients. A group of 97 sarcoi-
dosis patients and a matched group of 97 healthy controls took part in the study. Their QOL was examined by means of
the WHOQOL-BREF, and the respiratory functions were measured in sarcoidosis patients. The WHOQOL-BREF re-
vealed significantly poorer QOL of sarcoidosis patients in the domains of Physical and Psychological Health in compari-
son to healthy controls. In contrast, sarcoidosis patients perceived their QOL significantly better than healthy controls in
the domains of Social Relations and Environment. Differences between sarcoidosis patients and healthy controls were
found in several items from the WHOQOL-BREF and some of them were modified by gender. However, the WHOQOL-
-BREF did not prove to be a sensitive measure of fatigue, which is the most common symptom in sarcoidosis patients.
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Introduction
Quality of life (QOL) is defined as an individual per-
ception of well-being. Subject expresses his subjective
perception of the impact of health on quality of life. It is
affected by physical, material, social and emotional well-
-being, as well as many factors including financial status,
the environment we live and work in, people we connect
with. The QOL is overall well-being which can be influ-
enced by objective parameters as well as subjective per-
ception.
Several questionnaires are being used in scientific in-
vestigations and clinical practice, in order to assess qual-
ity of life in patients with respiratory diseases. Asthma
quality of life questionnaire (AQLQ) has proven as reli-
able and specific method in assessing QOL in asthma
patients1. Moreover, there are several questionnaires for
evaluating QOL in patients with COPD2. Several studies
evaluated QOL of sarcoidosis patients by means of the
World Health Organization Quality of Life Question-
naire WHOQOL-1003,4. The WHOQOL-100 was devel-
oped within a multicentre study to measure perceived
QOL in the context of the culture and value system in
which a person lives, and in relation to own goals, expec-
tations, standards and concerns. It enables detailed as-
sessment of 24 specific facets of quality of life, as well as
one general facet assessing the Overall Quality of Life
and General Health. The 24 specific facets are grouped
either into 6 broader domains of quality of life (Physical
Health, Psychological Health, Level of Independence, So-
cial Relations, Environment and Spirituality) or are con-
densed into 4 domains in the way that the domain of
Physical Health incorporates the Level of Independence
and the domain of Psychological Health incorporates
Spirituality5.
Studies that used the WHOQOL-100 in sarcoidosis
patients found the WHOQOL-100 to be a useful measure
of QOL. Due to the comprehensiveness of WHOQOL-100
(100 questions) it takes between 30 and 90 minutes to be
completed. The WHO developed a shorter form of the
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WHOQOL questionnaire, the WHOQOL-BREF, to be
less lengthy for participants. The aim of this study was to
examine whether the WHOQOL-BREF would be useful
for measuring QOL in sarcoidosis patients. Several au-
thors compared QOL of sarcoidosis patients with QOL of
patients diagnosed with rheumatoid arthritis5 and chro-
nic dermatosis6.
Therefore in this study we compared the estimate of
QOL obtained by the WHOQOL-BREF between a group
of sarcoidosis patients and a group of healthy controls.
Patients and Methods
Participants
Two groups of participants were included in the stu-
dy: a group of sarcoidosis patients (n=97), and a control
group of participants who stated they were healthy at the
time of examination (n=97). The group of sarcoidosis pa-
tients was examined at the University Hospital for Lung
Diseases »Jordanovac« in Zagreb. The control group was
examined at the Institute for Medical Research and Oc-
cupational Health in Zagreb. Patients were included in
the study on the basis of radiographic, functional and
clinical evidences of sarcoidosis. The participants of the
healthy control group were selected to match the partici-
pants of the sarcoidosis group for age, gender and level of
education.
Measures
Quality of life was measured by means the World
Health Organization Quality of Life Questionnaire
(WHOQOL-BREF). The WHOQOL-BREF is a generic
quality of life questionnaire which has been used with
different patient populations such as those suffering
from diabetes, rheumatoid diseases, mental diseases7,
AIDS8, and diseases of gastrointestinal system, as well as
with healthy population9. Twenty-four questions are
chosen from the original WHOQOL-100 questionnaire,
one per each facet, and 2 questions that refer to satisfac-
tion with Overall Quality of Life and General Health.
Other questions are divided into four domains of the
quality of life: Physical Health (7 items), Psychological
Health (6 items), Social Relations (3 items), and Envi-
ronment (8 items). Participants estimate the quality of
their lives during previous two weeks answering each
question on a Likert type scale from 1 to 5, 1 being for
lowest, and 5 highest agreement with the question. In
the WHOQOL-BREF mean estimate for all items in each
domain is transformed either to the range 4 to 20 or to
the range 0 to 100, so that the results could be compared
to the results in WHOQOL-100. Higher score in each do-
main indicates better QOL. In this study the transforma-
tion of the results in each domain was performed for the
theoretical range 4 to 20. High internal consistency and
test-retest stability were established for the results in
the Croatian version of the WHOQOL-BREF in a previ-
ous study10. Cronbach alpha coefficients were 0.82 for
Physical Health, 0.75 for Psychological Health, 0.66 for
Social Relations and 0.80 for Environment. Test-retest
stability established in a period of two to eight weeks was
0.66 for Physical Health, 0.72 for Psychological Health,
0.76 for Social Relations and 0.87 for Environment.
In patients with sarcoidosis respiratory functions
were also measured, which included spirometry and car-
bon monoxide diffusing capacity (DLCO). The functional
tests were performed at the Pulmonary function labora-
tory of the University Hospital for Lung Diseases »Jorda-
novac«.
All investigations were conducted in conformity with
ethical principles of research, and informed consent was
obtained from all participants in the study.
Statistical methods
Statistical analyses included the methods of descrip-
tive statistics, t-test for independent samples, c2 test,
analyses of variance and correlation analyses. The ac-
cepted level of significance was p<0.05.
Results
The analyses showed that the group of sarcoidosis pa-
tients did not differ in demographic characteristics and
smoking status from the group of healthy controls. With-
in each group differences in number of males and fe-
males were not statistically significant. Regarding other
demographic characteristics, the majority of participants
in both groups was married, had secondary school educa-
tion and was non-smokers. Demographic characteristics
and smoking status are presented in Table 1.
In sarcoidosis patients the mean FVC was 93.6%
(S.D.=17.2), FEV1 was 94.5% (S.D.=16.5), and DLco was
84.3% (S.D.=16.9).
The comparisons of the WHOQOL-BREF results by
domains were conducted by means of 2 x 2 ANOVAs. The
dependent variable in each analysis was a result in a par-
ticular domain of the quality of life, and the sources of
the between-subject variability in all analyses were Group
(sarcoidosis patients vs. healthy controls) and Gender
(males vs. females).
Sarcoidosis patients had lower scores in the domains
of Physical and Psychological Health than healthy con-
trols (F(1/190)=112.33, p<0.001, and F(1/191)=7.15, p<
0.01, respectively). However, in the domains of Social Re-
lations and Environment sarcoidosis patients obtained
significantly higher scores than healthy controls (F(1/191)
=9.95, p<0.01, and F(1/191)=17.31, p<0.001, respec-
tively). Data are summarized in Table 2.
Further comparisons of the results for each item of
the WHOQOL-BREF were conducted by means of 2 x 2
ANOVAs with Group (sarcoidosis patients vs. healthy
controls) and Gender (male vs. females) as sources of the
between-subject variability.
Regarding the general estimate of quality of life (Q1)
and general satisfaction with health status (Q2) sarcoi-
dosis patients did not differ statistically significantly
from healthy controls. However, the significant main ef-
M. Alilovi} et al.: WHOQOL-BREF – a Measure of QOL in Sarcoidosis, Coll. Antropol. 37 (2013) 3: 701–706
702
fects of Group were found for Q3 (F(1/188)=292.88,
p<0.001) and Q4 (F(1/188)=175.02, p<0.001) within the
domain of Physical Health. In comparison to healthy
controls sarcoidosis patients perceived more limitations
in activities due to pain (Q3) and were more in need of
medical treatment (Q4). Significant interaction of Group
and Gender found for Q3 (F(1/188)=11.48, p=0.001) and
Q4 (F(1/188)=5.65, p<0.05) indicated that in perception
of limitations due to pain (Q3) and need of medical treat-
ment the effects of sarcoidosis were somewhat more pro-
nounced in males than in females. Significant interaction
of Group and Gender was also found for Q16 (F(1/188)=
6.27, p<0.05), indicating that in females satisfaction
with sleep was lower in patients than in healthy controls,
while in males there were no differences in satisfaction
with sleep between the patients and healthy controls.
Within the domain of Psychological Health significant
main effects of Group were found for Q5 (F(1/188)=4.82,
p<0.05) and Q26 (F(1/188)=163.82, p<0.001). Sarcoido-
sis patients estimated their enjoyment in life (Q5) higher
than healthy controls. At the same time they reported
negative feelings (Q26) more often than healthy individ-
uals. Significant interaction of Group and Gender for
Q26 (F(1/188)=4.10, p<0.05) indicated that male sarcoi-
dosis patients reported negative feelings more often than
female, in comparison to healthy controls of the same
gender. Within the domain of Psychological Health we
observed also a significant main effect of Gender for Q19
(F(1/188)=5.78, p<0.05), indicating that men were gen-
erally more satisfied with themselves (M=4.125, S.D.=
0.682) than women (M=3.898, S.D.=0.610).
Within the domain of Social Relations a significant
main effect of Group was found for Q21 (F(1,188)=7.99,
p<0.01). Sarcoidosis patients rated their satisfaction with
sex life higher than did healthy controls. The ANOVA
yielded a significant main effect of Group for Q22 (F(1,188)=
19.91, p<0.001), as well as a significant interaction be-
tween Group and Gender (F(1,188)=7.78, p<0.01). The
main effect of Group needs to be interpreted in light of
the significant interaction since higher satisfaction with
support from friends was found in sarcoidosis patients in
comparison to healthy controls only for males, but not
for females.
Within the domain of Environment significant differ-
ences between sarcoidosis patients and healthy individu-
als were found in Q9 (F(1,188)=11.13, p=0.001), Q12
(F(1,188)=24.12, p<0.001), Q23 (F(1,188)=4.27; p<0.05),
Q24 (F(1,188)=29.31, p<0.001) and Q25 (F(1,188)=7.36;
p<0.01). They showed that in comparison to healthy con-
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TABLE 2
ESTIMATED MARGINAL MEANS AND STANDARD ERRORS OF





M S.E. M S.E.
Physical Health 13.69 0.18 16.36 0.18
Psychological Health 14.96 0.17 15.61 0.17
Social Relations 16.69 0.24 15.64 0.24
Environment 15.52 0.18 14.46 0.18
TABLE 1
DEMOGRAPHIC CHARACTERISTICS AND SMOKING STATUS WITH TESTS FOR WITHIN-GROUP AND
BETWEEN-GROUP COMPARISONS
Characteristics Sarcoidosis patients (n=97) Healthy controls (n=97) Comparison between groups















































trols sarcoidosis patients rated their environment
healthier (Q9), and perceived higher satisfaction with
their financial resources (Q12), conditions of living place
(Q23), access to health services (Q24) and transport
(Q25). Significant interaction between Group and Gen-
der for Q24 (F(1,188)=4.18, p<0.05) indicated that satis-
faction with access to health services increased more in
male sarcoidosis patients than in female, in comparison
to healthy controls of the same gender. Within the do-
main of Environment we observed also the significant
main effect of Gender for Q14 (F(1,188)=6.42, p<0.05)
indicating that men were generally more satisfied with
opportunities for recreation (M=3.462, S.D.=0.795) in
comparison to women (M=3.130, S.D.=0.987). We ob-
served the significant main effect of Gender also for Q23
(F(1,188)=5.45, p<0.05), indicating that men we gener-
ally more satisfied with conditions of their living place
(M=3.462, S.D.=0.795) than women (M=3.130, S.D.=
0.987). Data are presented in Table 3.
The correlations between age and results on four do-
mains of the WHOQOL – BREF were not statistically
significant neither in the group of sarcoidosis patients
(r=–0.03 for Physical Health, r=–0.14 for Psychological
Health, r=0.10 for Social Relations, r=0.00 for Environ-
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TABLE 3
MEAN ESTIMATES AND STANDARD DEVIATIONS FOR EACH WHOQOL-BREF ITEM













Q1 Overall Quality of Life 4.000 (0.506) 3.947 (0.789) 3.969 (0.684) 3.775 (0.660) 3.843 (0.579) 3.813 (0.613)
Q2 General Health 3.700 (0.608) 3.544 (0.657) 3.608 (0.638) 3.825 (0.636) 3.765 (0.885) 3.791 (0.782)
Physical Health
Q3 Pain 1.875 (0.822) 2.439 (0.907) 2.206 (0.912) 4.500 (0.751) 4.196 (0.938) 4.330 (0.870)
Q4 Dependence on medical treatment 2.075 (0.829) 2.298 (0.801) 2.206 (0.816) 4.325 (0.797) 3.863 (1.327) 4.066 (1.143)
Q10 Energy 4.075 (0.829) 3.790 (0.818) 3.907 (0.830) 4.075 (0.730) 3.980 (0.735) 4.022 (0.730)
Q15 Mobility 4.250 (0.707) 3.965 (0.706) 4.082 (0.717) 4.150 (0.921) 4.235 (0.971) 4.198 (0.945)
Q16 Sleep 3.875 (0.686) 3.649 (0.612) 3.742 (0.650) 3.650 (0.949) 4.020 (0.948) 3.857 (0.961)
Q17 Activities of daily living 3.950 (0.678) 3.825 (0.630) 3.876 (0.650) 3.950 (0.714) 4.020 (0.707) 3.989 (0.707)
Q18 Working capacity 4.050 (0.846) 3.790 (0.773) 3.897 (0.810) 4.100 (0.709) 4.078 (0.717) 4.088 (0.709)
Psychological Health
Q5 Positive feelings 3.800 (0.464) 3.719 (0.675) 3.753 (0.596) 3.525 (0.816) 3.529 (0.833) 3.528 (0.821)
Q6 Meaningfulness of life 4.375 (0.705) 4.263 (0.669) 4.309 (0.682) 4.275 (0.679) 4.275 (0.826) 4.275 (0.761)
Q7 Concentration 3.725 (0.640) 3.807 (0.718) 3.773 (0.685) 3.800 (0.608) 3.882 (0.816) 3.846 (0.729)
Q11 Body appearance 4.225 (0.862) 4.088 (0.786) 4.144 (0.816) 4.325 (0.829) 4.137(1.020) 4.220 (0.940)
Q19 Satisfaction with oneself 4.225 (0.660) 3.912 (0.576) 4.041 (0.628 4.025 (0.698) 3.882 (0.653) 3.945 (0.673)
Q26 Negative feelings 2.300 (0.564) 2.456 (0.629) 2.392 (0.605) 3.750 (0.670) 3.510 (0.758) 3.615 (0.727)
Social Relations
Q20 Personal relations 4.075 (0.997) 4.193 (0.611) 4.144 (0.790) 4.150 (0.662) 4.000 (0.916) 4.066 (0.814)
Q21 Sex life 4.225 (0.577) 3.877 (0.781) 4.021 (0.721) 3.675 (0.764) 3.726 (1.097) 3.703 (0.960)
Q22 Support from friends 4.425 (0.636) 4.246 (0.606) 4.320 (0.622) 3.700 (0.687) 4.078 (0.770) 3.912 (0.755)
Environment
Q8 Physical safety 3.650 (0.622) 3.684 (0.631) 3.670 (0.624) 3.850 (0.834) 3.863 (0.693) 3.857 (0.754)
Q9 Healthy physical environment 3.625 (0.586) 3.596 (0.623) 3.608 (0.605) 3.275 (0.816) 3.255 (0.770) 3.264 (0.786)
Q12 Financial resources 3.600 (0.810) 3.895 (0.900) 3.773 (0.872) 3.050 (0.932) 3.118 (0.993) 3.088 (0.962)
Q13 Availability of information 3.850 (0.736) 4.210 (0.590) 4.062 (0.674) 3.950 (0.750) 3.961 (0.871) 3.956 (0.815)
Q14 Opportunities for leisure activities 3.375 (0.668) 3.246 (0.662) 3.299 (0.664) 3.550 (0.904) 3.000 (1.249) 3.242 (1.139)
Q23 Home environment 4.100 (0.871) 4.158 (0.882) 4.134 (0.874) 3.550 (1.108) 4.137 (0.895) 3.879 (1.031)
Q24 Access to health services 4.450 (0.597) 4.140 (0.666) 4.268 (0.654) 3.575 (0.958) 3.745 (0.913) 3.670 (0.932)
Q25 Transport 4.300 (0.758) 4.193 (0.693) 4.237 (0.718) 3.850 (0.949 3.941 (1.066) 3.901 (1.012)
Note: Higher score in all items indicate better quality of life. Mean values are presented in bold for the statistically significant main ef-
fect of Group, and interaction of Group and Gender
ment) nor in the group of healthy controls (r=–0.06 for
Physical Health, r=–0.16 for Psychological Health, r=
–0.15 for Social Relations, r=0.01 for Environment). In
the group of sarcoidosis patients moderate correlations
were found between the pulmonary function parameters
and quality of life in the domains of Physical Health and
Psychological Health. Correlations between pulmonary
functions parameters and quality of life in the domains of
Social Relations and Environment were small or were
not statistically significant, as presented in Table 4.
Discussion
The results of our study suggest that there is a differ-
ence in QOL between groups that were investigated. A
group of 97 sarcoidosis patients and a matched group of
97 healthy individuals were included in this study. Ac-
cording to the Cummins program, a balanced model of
quality of life should be unchangeable during life11. How-
ever, our study has shown that there is a difference in
quality of life when comparing persons affected by the
disease and healthy individuals.
There was no significant difference between sarcoi-
dosis patients and healthy controls with respect to age,
gender, smoking habits and marital status. The average
age of sarcoidosis patients was 42.4 years of age, and of
healthy individuals 42.7. According to the literature, the
incidence and prevalence of sarcoidosis is at peek be-
tween 20 and 40 years of age. The average age of sar-
coidosis patients in USA is around 40 years of age12, and
41.5 in Denmark13. It is well documented that sarcoidosis
affects more women than men, as seen in our group. In
Japan, Spain and according to researches in Croatia
sarcoidosis can more often be seen in females14. Accord-
ing to numerous studies sarcoidosis affects mostly non-
-smokers, which has been proven in sarcoidosis patients
in Croatia as well.
There was no significant difference between sarcoi-
dosis patients and healthy individuals when comparing
estimates of Overall Quality of Life and General Health.
However, our results showed differences in the domain of
Physical Health. Questions regarding Physical Health
were connected to daily activities, working capacity, en-
ergy, mobility, pain and sleeping. Sarcoidosis patients
were more limited due to pain and needed greater medi-
cal assistance. These difficulties were greater in men.
Comparing to healthy controls women were less satisfied
with sleeping than men. Moreover, within the domain of
Psychological Health there was significant difference be-
tween sarcoidosis patients and healthy controls. Ques-
tions related to this domain included positive and nega-
tive feelings, memory and concentration. Although
sarcoidosis patients more often expressed more enjoy-
ment in life, they also more often expressed negative feel-
ings. These negative feelings and reduction of concentra-
tion usually reflect a depressive syndrome. According to
the literature, temporary depression in sarcoidosis pa-
tients which manifests itself as nervousness, anger and
anxiety, can be seen more often in women15. In our group
of sarcoidosis patients, in contrast to the literature, men
complained more often of pain and negative feelings. On
the other hand, men also gave the opinions to the con-
trary, and were more satisfied with themselves, their sex
life, medical treatment, environment and support from
friends.
Our study demonstrated that sarcoidosis patients
have better results than healthy individuals within the
domain of Social Relations and Environment. We could-
n’t find explanation for better patients' results in the do-
main of Social Relations and Environment neither in our
results nor in literature. Questions related to this do-
main included physical safety, energy, mobility, access to
health services, financial resources, home environment,
as well as questions concerning satisfaction with oneself,
support from friends, personal relations, sex life and
healthy physical environment.
In two studies conducted in the Netherlands QOL of
sarcoidosis patients was compared to those of healthy in-
dividuals, and the results were similar to ours. They
demonstrated that sarcoidosis patients with current
symptoms estimated their quality of life to be lower in
comparison to healthy controls in the domain of Physical
Health and Level of Independence, as well as in the facet
of Overall Quality of Life and General Health. Patients
currently reporting symptoms did differ from healthy in-
dividuals in the facet of negative feelings within the do-
main of Psychological Health, while there was no signifi-
cant difference in the domain scores for Social Relations
and Environment. All sarcoidosis patients taken to-
gether, irrespective whether they were currently report-
ing symptoms or not, rated their Overall Quality of Life,
General Health, and the QOL in the domain of Physical
Health lower than healthy individuals. However, sarcoi-
dosis patients that were currently not affected by active
disease evaluated their QOL better than healthy individ-
uals in the domain of Social Relations and Environ-
ment16. Similar results were documented in our study.
Some psychologists offer an explanation for this illogical-
ity. They believe that the reduction of QOL in one do-
main is compensated by an augmentation in another do-
main. Due to illness, imbalance of quality of life occurs
and patients strive to retrieve the balance17.
We documented the reduction of QOL of sarcoidosis
patients in the domain of Physical and Psychological
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TABLE 4
PEARSON CORRELATIONS OF PULMONARY FUNCTION
PARAMETERS WITH RESULTS IN FOUR DOMAINS OF








FVC 0.429** 0.390** 0.249* 0.190
FEV1 0.399** 0.341** 0.274** 0.196
DLco 0.362** 0.304** 0.116 0.190
** p<0.01, * p<0.05
Health by using WHOQOL-BREF questionnaire. Based
on this questionnaire we did not obtain any information
regarding fatigue, which is the most significant symptom
of sarcoidosis. According to the literature, fatigue is one
of the main causes of reduced QOL in sarcoidosis pa-
tients. Recent studies show that 60% of sarcoidosis pa-
tients in Croatia18 and 73% in Netherlands19 report per-
sistent fatigue. Our results show correlation of age and
QOL. Moderate correlation between pulmonary func-
tions parameters and QOL in the domains of Physical
and Psychological Health, and small correlation with So-
cial Relations were documented.
Our results show that measuring pulmonary func-
tions parameters is insufficient for evaluating QOL.
Questionnaires for evaluating QOL should be used be-
cause they give more precise and complete assessment of
overall health status. The WHOQOL-BREF question-
naire, as opposed to expert opinion20 of other specialists
is not sufficient for the evaluation of QOL in sarcoidosis
patients, thus additional scale for assessing fatigue
should be used for obtaining better QOL evaluation.
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WHOQOL-BREF UPITNIK KAO MJERA KVALITETE @IVOTA KOD BOLESNIKA SA SARKOIDOZOM
S A @ E T A K
Cilj ovog istra`ivanja je bio procijeniti korisnost kratkog oblika WHOQOL upitnika, WHOQOL-BREF, koji se sastoji
od 24 pitanja, u procjeni kvalitete `ivota bolesnika sa sarkoidozom. U istra`ivanje je bilo uklju~eno 97 bolesnika sa
sarkoidozom i kontrolna skupina od 97 zdravih ispitanika. Njihova kvaliteta `ivota je ispitivana WHOQOL-BREF upit-
nikom, a bolesnicima sa sarkoidozom su u~injeni i funkcijski testovi. WHOQOL-BREF upitnik je pokazao zna~ajnije
manju kvalitetu `ivota bolesnika u podru~ju fizi~kog i psihi~kog zdravlja u usporedbi s kontrolnom skupinom. Nasuprot
tome bolesnici sa sarkoidozom su pokazali bolju kvalitetu `ivota u podru~ju socijalnih odnosa i okoline. Razlike izme|u
bolesnika sa sarkoidozom i kontrolne skupine u pojedinim podru~jima bile su u interakciji sa spolom. WHOQOL-BREF
upitnik nije se pokazao kao dobra mjera u procjeni umora koji je jedan od naj~e{}ih simptoma bolesnika sa sarkoidozom.
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